Prelude Therapeutics Incorporated

Quetzal Therapeutics, LLC

Syros Pharmaceuticals, Inc.

Krishna Vaddi

Juan Luengo

Hong Lin

Rupa S Shetty

Kumar Kurumaddali

Raul A Leal

Described herein are methods of treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in need thereof. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas, and solid tumors including glioblastoma multiforme and breast cancer. Also described herein are oral pharmaceutical formulations comprising lyophilized compositions comprising arsenic and methods for lyophilizing arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and treating a subject with malignancies using the oral formulation.

Lyophilized compositions comprising arsenic

The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described. 

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Growing community of inventors

Chadds Ford, PA, United States of America

Krishna Vaddi